Kinase News and Research

RSS

HIPK2 regulator protein plays a crucial role in kidney fibrosis

Researchers from Mount Sinai School of Medicine have identified a regulator protein that plays a crucial role in kidney fibrosis, a condition that leads to kidney failure. Finding this regulator provides a new therapeutic target for the millions of Americans affected by kidney failure. The research is published in the March 11 issue of Nature Medicine.

12 Mar 2012

Celgene acquires Avila Therapeutics

Celgene Corporation today announced it has completed its acquisition of Avila Therapeutics. Celgene acquired Avila Therapeutics for $350 million in cash, plus up to $575 million contingent upon certain milestones related to AVL-292 and candidates from Avila's discovery program.

9 Mar 2012

Celldex fourth quarter net loss increases to $12.7 million

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2011.

8 Mar 2012

Scientists identify novel protein expressed by breast cancer cells

A team of scientists at the University of California, San Diego Moores Cancer Center has identified a novel protein expressed by breast cancer cells - but not normal adult tissues - that could provide a new target for future anti-cancer drugs and treatments.

6 Mar 2012

$Millennium commences MLN8237 phase 3 trial in relapsed or refractory PTCL$

Millennium commences MLN8237 phase 3 trial in relapsed or refractory PTCL

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), an aggressive form of lymphoma.

5 Mar 2012

SuperFAK protein decreases damage from heart attack by 50%

Researchers from the University of North Carolina at Chapel Hill reduced damage from a heart attack by 50 percent by enhancing a protective protein found in mice and humans.

2 Mar 2012

Ruxolitinib boosts QOL and survival for patients with myelofibrosis

A drug that relieves the severe symptoms of a life-threatening bone marrow cancer called myelofibrosis also improves the survival of patients with the disease, according to a phase III clinical trial published in the March 1 edition of New England Journal of Medicine.

1 Mar 2012

Creabilis initiates CT327 Phase IIb trial in psoriasis vulgaris

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today announced the start of the Phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris. Recruitment is progressing well.

29 Feb 2012

Aurora-A protein blocks proper functioning of tumor-suppressor p73

A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.

28 Feb 2012

Biodesix, Kadmon enter Phase 3 non-small cell lung cancer study collaboration

Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix' VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon's KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.

27 Feb 2012

Exelixis announces cabozantinib preclinical data on pancreatic cancer

Exelixis, Inc. today announced the company's lead compound, cabozantinib, is highlighted in a new peer-reviewed publication demonstrating that simultaneous inhibition of MET and VEGF signaling reduces tumor invasiveness and metastasis in preclinical models of pancreatic cancer.

26 Feb 2012

Vemurafenib nearly doubles survival for patients with metastatic melanoma

Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.

23 Feb 2012

Researchers discover mechanism of thermostat protein

Johns Hopkins and National Taiwan University researchers have discovered more details about how an energy sensing "thermostat" protein determines whether cells will store or use their energy reserves.

22 Feb 2012

OGF-OGFr axis discovery provides new insights into ovarian cancer

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the presence and integrity of the opioid growth factor receptor (OGFr), which mediates the inhibitory action of opioid growth factor (OGF) on cell proliferation, is a key to understanding the progression and treatment of human ovarian cancer.

22 Feb 2012

New details about how cell signalling is controlled in immune system

Walter and Eliza Hall Institute scientists have revealed new details about how cell signalling is controlled in the immune system, identifying in the process potential new therapeutic targets for treating severe blood disorders.

17 Feb 2012

Gene sequencing could identify genetic variants of lung cancer and colorectal cancer

Foundation Medicine Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute have come up with the results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases.

14 Feb 2012

'Targeted' drugs may be effective against lung and colorectal tumors driven by novel gene abnormalities

Novel gene abnormalities discovered in a subpopulation of lung and colorectal tumors could potentially identify patients with a good chance of responding to highly specific "targeted" drugs already in use for treating other cancers, scientists report.

14 Feb 2012

Scientists create new mouse model for medulloblastoma

Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) developed a new mouse model for studying a devastating childhood brain cancer called medulloblastoma.

14 Feb 2012

Erasing neuronal memories may help control persistent pain

For some, the pain is so great that they can't even bear to have clothes touch their skin. For others, it means that every step is a deliberate and agonizing choice. Whether the pain is caused by arthritic joints, an injury to a nerve or a disease like fibromyalgia, research now suggests there are new solutions for those who suffer from chronic pain.

13 Feb 2012

Discovery of novel rearrangements and fusions supports role for NGS in treatment of cancer

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute today announced the Nature Medicine publication of results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases.

13 Feb 2012